Chemiluminescent enzyme immunoassay for measuring leptin

Area of Science:

• Biochemistry
• Immunology
• Assay Development

Background:

• Leptin, an adipocyte-derived hormone, is crucial for metabolic regulation.
• Serum leptin concentration is a key biomarker for diabetes mellitus and other diseases.
• Accurate leptin measurement is essential for clinical diagnostics and therapeutic monitoring.

Purpose of the Study:

• To develop and validate a sensitive chemiluminescent enzyme immunoassay (CLEIA) for quantifying serum leptin.
• To optimize blocking agents for minimizing non-specific binding in the assay.
• To evaluate the assay's sensitivity, measurable range, and clinical applicability.

Main Methods:

• Construction of a CLEIA using anti-leptin polyclonal antibody and alkaline phosphatase (ALP).
• Utilized IgG-conjugated ferrite particles for leptin capture and ALP-conjugated Fab fragments for detection.
• Evaluated bovine serum albumin (BSA), Block ace, and CE510 for blocking non-specific binding.

Main Results:

• Bovine serum albumin (BSA) was identified as the most effective blocking agent.
• The developed CLEIA achieved a measurable range of 0.1-1.0 pg/mL for leptin.
• The assay exhibited a low detection limit of 0.1 pg/mL, indicating high sensitivity.

Conclusions:

• The developed CLEIA is a sensitive and clinically useful method for measuring serum leptin concentrations.
• The assay's performance supports its application in preventing and treating leptin-related diseases.
• This study highlights the feasibility of constructing sensitive enzyme immunoassays using a single polyclonal antibody.